Immunization for meningococcal serogroup B: What does the practitioner need to know?

Area of Science:

• Public Health
• Vaccinology
• Epidemiology

Background:

• Invasive meningococcal disease (IMD) in Canada is predominantly caused by serogroup B.
• Serogroup B IMD poses a significant public health concern due to its potential for severe outcomes.

Purpose of the Study:

• To evaluate the implications of the newly licensed 4-component serogroup B meningococcal vaccine (4CMenB) for routine infant immunization in Canada.
• To inform decision-making for provincial and territorial public health authorities regarding the adoption of 4CMenB into infant immunization schedules.

Main Methods:

• This is a decision-making analysis based on existing epidemiological data and vaccine information.
• Consideration of vaccine effectiveness, safety profile (specifically fever incidence), and logistical challenges of adding new vaccines to the schedule.

Main Results:

• The decision involves balancing the potential to prevent rare but serious mortality and morbidity against vaccine-related factors.
• Uncertainty in vaccine effectiveness and the high incidence of fever are key considerations.
• The burden of additional injections in the existing immunization schedule is a significant factor.

Conclusions:

• A comprehensive assessment is required to determine if a routine infant immunization program with 4CMenB is warranted in Canada.
• Public health policy decisions must weigh the benefits of preventing serogroup B IMD against vaccine-specific challenges and uncertainties.